Favorites Sign in

One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
  1. Home
  2. Companies
  3. Amgen
  4. Financial Ratios
Amgen logo
Amgen AMGN
$ 462.71 -3.32%
report update icon

Quarterly report 2026-Q2
added 08-29-2026

Amgen Financial Ratios 2025-2006 | AMGN

Brief overview of Amgen's valuation and returns

Current figures are compared with the company's own five-year history for 2021–2025.

The current valuation set is P/E 25.73x (median 23.1x), EV/EBITDA 10.74x (median 13.18x), P/S 5.4x (median 4.9x). Ratios sit near their own comparison base, with an average deviation of +10.6% from five-year medians.

At the current P/E, inverse earnings yield is 3.9%, a useful bridge between price and business earnings.

Capital efficiency is characterized by ROE 89.1%, ROA 8.5%, ROCE 104.9%. Current resource returns are convincing and help explain a higher market valuation.

The PEG ratio is 5.35x; investors pay a high price per unit of expected growth.

The cash conversion cycle is 216.9 days versus 213 days initially. Turnover changed little.

Conclusion

Amgen's profile looks neutral, with price and fundamental efficiency broadly aligned.

Annual Financial Ratios Amgen

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006

P/E

 25.7 38.3 23.1 19.7 21.5 17.3 17.4 14.6 70.7 15.0 16.7 22.4 17.9 15.2 16.8 10.5 11.1 11.7 20.7 -

P/S

 5.4 4.7 5.5 4.9 4.9 4.9 5.9 5.1 6.1 5.0 5.3 5.8 4.9 3.8 4.0 3.2 3.5 3.2 4.3 -

EPS

 14.3 7.6 12.6 12.2 10.3 12.4 13.0 12.7 2.7 10.3 9.2 6.8 6.8 5.6 4.1 4.8 4.5 3.8 2.8 -

EV (Enterprise Value)

 189 B 145 B 144 B 121 B 119 B 119 B 181 B 169 B 191 B 160 B 155 B 155 B 131 B 98.2 B 84.7 B 45.4 B 48 B 45.5 B 61.6 B -1.28 B

EBITDA per Share

 26.5 23.9 22.4 24.1 19.4 21.7 19.6 18.5 16.3 15.9 14 10.9 9.5 7.58 6.08 6.84 6.45 5.88 4.64 -

EV/EBITDA

 13.3 11.2 12.0 9.4 10.7 13.2 13.5 12.2 14.4 12.3 13.5 17.2 16.7 15.2 13.9 6.9 7.3 7.2 11.9 -

PEG

 5.35 7.95 4.93 2.24 4.93 1.85 8.52 0.04 -0.96 1.17 0.48 30.25 0.88 0.4 -1.08 - - - - -

P/B

 2.2 1.7 1.6 2.0 2.1 2.0 14.1 9.8 5.5 3.9 4.1 4.5 4.1 3.5 3.2 1.1 1.3 1.3 - -

P/CF

 19.9 13.6 18.3 13.3 13.7 12.0 16.0 11.6 13.3 12.1 13.7 15.3 16.3 12.7 13.6 8.4 8.0 7.9 11.8 -

ROE %

 89.06 69.59 107.78 178.97 87.96 77.20 81.07 67.15 7.84 25.85 24.71 20.01 23.00 22.80 19.35 19.32 20.32 19.40 16.63 -

ROA %

 8.51 4.45 6.91 10.06 9.63 11.54 13.13 12.64 2.48 9.95 9.69 7.47 7.68 8.00 7.54 10.64 11.62 11.12 - -

ROCE %

 104.87 123.50 126.72 261.29 114.01 97.13 20.64 19.39 14.06 14.75 13.46 9.99 10.08 12.10 12.08 23.16 24.29 24.97 21.50 -

Current Ratio

 - - - - - - 1.4 2.8 5.5 4.1 4.4 5.0 3.4 3.8 4.8 - - - - -

DSO

 81.2 76.7 83.1 72.5 66.2 61.6 63.4 55.0 51.7 50.2 50.5 46.3 52.7 53.2 67.8 53.9 52.1 25.2 - -

DIO

 200.5 234.4 312.0 256.9 225.6 221.6 300.3 261.7 254.2 240.7 210.3 218.5 329.3 343.2 373.6 - - - - -

DPO

 64.8 49.6 68.3 83.7 78.8 82.7 114.9 107.4 121.3 80.4 83.3 100.0 85.9 113.2 96.6 - - - - -

Operating Cycle

 281.7 311.1 395.1 329.4 291.8 283.2 363.7 316.7 305.9 291.0 260.7 264.8 382.0 396.5 441.4 53.9 52.1 25.2 - -

Cash Conversion Cycle

 216.9 261.5 326.8 245.7 213.0 200.4 248.8 209.3 184.6 210.6 177.4 164.8 296.2 283.3 344.9 53.9 52.1 25.2 - -

All numbers in USD currency

Quarterly Financial Ratios Amgen

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1 2010-Q4 2010-Q3 2010-Q2 2010-Q1 2009-Q4 2009-Q3 2009-Q2

EPS

 2.66 3.22 6.11 5.27 1.39 -0.21 - 3.23 2.58 5.32 - 3.23 2.46 2.69 - 4.01 - 2.69 - 3.32 0.81 2.85 2.78 3.45 3.07 3.09 2.87 3.29 3.59 3.2 3.04 2.88 3.5 3.27 -5.89 2.78 2.93 2.81 2.61 2.7 2.49 2.52 2.39 2.46 2.18 2.13 1.7 1.63 2.04 1.42 1.35 1.81 1.67 1.91 1.03 1.44 1.63 1.5 1.09 0.5 1.26 1.21 0.99 1.36 1.25 0.99 -0.15000000000000036 1.06 0.84

EBITDA per Share

 6.98 4.42 -1.28 K 6.05 5.79 4.09 - 5.07 6.31 4.9 - 5.07 5.24 5.72 - 6.15 - 6.1 - 5.33 2.58 5.15 - 8.86 7.06 5.51 - 6.64 6.05 4.77 - 5.86 5.77 4.52 - 5.42 5.1 4.23 - 5.45 4.56 3.88 - 5.16 4.1 3.35 - 3.99 3.86 2.49 - 3.36 2.8 2.29 - 2.9 2.73 2.19 - 1.46 2.01 1.68 13.7 1.85 1.69 1.54 7.29 1.4 1.09

ROE %

 188.10 175.70 144.45 133.17 165.36 230.99 232.81 255.40 199.83 144.26 66.66 125.32 263.86 264.76 242.73 248.35 189.69 207.32 46.19 63.35 61.90 75.44 77.20 77.64 76.51 79.87 81.07 78.89 73.42 69.26 67.15 34.83 27.97 18.12 7.84 31.21 29.96 27.69 25.85 25.78 25.66 25.29 24.71 23.32 21.51 21.63 20.01 19.61 20.98 20.67 23.00 22.51 22.13 23.07 22.80 23.57 20.15 19.65 19.35 19.95 23.68 23.13 21.71 15.96 15.21 13.95 -0.25 5.37 4.34

ROA %

 10.12 9.35 7.31 6.69 6.54 8.65 8.77 10.68 10.03 9.37 6.44 8.94 9.93 8.44 6.17 6.17 6.17 8.80 6.31 8.87 9.18 11.27 11.54 11.83 11.91 12.70 13.13 13.18 12.69 12.50 12.64 4.40 4.13 3.36 2.48 10.30 10.37 10.09 9.95 9.97 9.98 9.89 9.71 9.07 8.27 8.19 7.48 7.14 7.41 7.07 7.68 7.59 7.56 7.99 8.00 8.46 7.35 7.41 7.54 8.20 10.76 11.57 11.84 9.14 8.72 8.00 -0.13 3.08 2.49

ROCE %

 178.66 164.10 159.96 134.58 175.05 196.89 180.99 207.39 184.66 148.66 96.19 169.01 415.53 412.00 374.68 384.72 311.91 334.71 61.79 87.86 83.61 98.60 75.79 101.39 103.00 103.87 78.84 97.42 94.48 88.60 63.05 72.71 64.82 52.42 30.62 39.08 37.38 34.73 24.47 32.79 31.73 30.96 22.92 28.61 27.66 25.56 18.36 26.00 27.32 26.47 21.18 28.65 29.34 30.08 23.55 26.31 25.84 24.30 16.55 21.04 25.36 24.79 23.83 18.85 18.87 18.08 -0.49 7.10 5.65

DSO

 95.1 91.5 160.7 72.8 73.8 86.1 - 96.1 94.9 95.9 - 77.4 77.0 81.4 - - - 72.9 - 62.9 62.2 69.2 - 64.3 66.5 63.5 - 64.5 63.1 62.7 - 55.3 53.9 56.0 - 51.2 50.8 53.5 - 49.7 50.8 50.9 - 47.8 50.9 50.2 - 46.2 44.9 52.9 - 51.8 52.6 56.1 - 53.2 51.3 61.0 - 67.0 66.8 61.6 46.1 50.5 51.8 57.7 53.8 48.8 -

DIO

 188.7 203.3 -493.1 192.9 197.3 235.5 - 480.9 479.1 383.2 - 251.5 297.9 288.2 - - - 248.3 - 234.4 226.7 242.2 - 227.6 238.7 225.5 - 315.7 323.2 282.1 - 258.7 262.0 279.1 - 261.2 252.5 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DPO

 71.7 65.7 -134.4 52.6 53.8 49.9 - 80.3 80.0 83.9 - 74.0 95.0 91.9 - - - 80.9 - 69.4 74.5 86.3 - 83.1 87.1 84.2 - 120.8 123.6 111.5 - 106.2 107.6 123.7 - 124.6 120.5 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

 - - - - - - - - - - - 328.9 - - - - - 321.3 - 297.3 288.9 311.4 - 291.9 305.3 289.0 - 380.2 386.2 344.8 - 314.0 315.9 335.1 - 312.4 303.4 53.5 - 49.7 50.8 50.9 - 47.8 50.9 50.2 - 46.2 44.9 52.9 - 51.8 52.6 56.1 - 53.2 51.3 61.0 - 67.0 66.8 - - - - - - - -

Cash Conversion Cycle

 - - - - - - - - - - - 254.9 - - - - - 240.4 - 227.9 214.4 225.1 - 208.8 218.1 204.8 - 259.4 262.6 233.3 - 207.8 208.3 211.4 - 187.8 182.9 53.5 - 49.7 50.8 50.9 - 47.8 50.9 50.2 - 46.2 44.9 52.9 - 51.8 52.6 56.1 - 53.2 51.3 61.0 - 67.0 66.8 - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Amgen, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Trillium Therapeutics Inc. Trillium Therapeutics Inc.
TRIL
 		- - $ 1.94 B canadaCanada
Exicure Exicure
XCUR
 		$ 0.89 -10.34 % $ 5.6 M usaUSA
Urovant Sciences Ltd. Urovant Sciences Ltd.
UROV
 		- - $ 532 M britainBritain
Acceleron Pharma Inc. Acceleron Pharma Inc.
XLRN
 		- - $ 10.9 B usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
 		- 0.52 % $ 821 M danmarkDanmark
Zogenix, Inc. Zogenix, Inc.
ZGNX
 		- -4.97 % $ 664 M usaUSA
Yunhong International Yunhong International
ZGYH
 		- 0.10 % $ 92.2 M chinaChina
ZIOPHARM Oncology, Inc. ZIOPHARM Oncology, Inc.
ZIOP
 		- -7.58 % $ 264 M usaUSA
Xenon Pharmaceuticals Xenon Pharmaceuticals
XENE
 		$ 37.65 -3.93 % $ 2.98 B canadaCanada
Leap Therapeutics Leap Therapeutics
LPTX
 		- 368.57 % $ 41.9 M usaUSA
Zymeworks Zymeworks
ZYME
 		$ 28.83 -6.82 % $ 1.49 B canadaCanada
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
 		$ 3.15 -35.42 % $ 2.11 M usaUSA
ADMA Biologics ADMA Biologics
ADMA
 		$ 13.2 25.91 % $ 3.15 B usaUSA
Cortexyme Cortexyme
CRTX
 		- -1.05 % $ 67.1 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
 		$ 3.94 -5.52 % $ 863 M britainBritain
Daré Bioscience Daré Bioscience
DARE
 		$ 0.62 -3.5 % $ 6.93 M usaUSA
Fate Therapeutics Fate Therapeutics
FATE
 		$ 1.86 -11.24 % $ 221 M usaUSA
Greenwich LifeSciences Greenwich LifeSciences
GLSI
 		$ 14.63 -10.55 % $ 198 M usaUSA
Halozyme Therapeutics Halozyme Therapeutics
HALO
 		$ 123.1 -5.55 % $ 14.8 B usaUSA
Hutchison China MediTech Limited Hutchison China MediTech Limited
HCM
 		$ 14.15 1.65 % $ 12.1 B chinaChina
Aptorum Group Limited Aptorum Group Limited
APM
 		- - $ 5.72 M chinaChina
iBio iBio
IBIO
 		$ 0.73 -8.74 % $ 76 M usaUSA
Kodiak Sciences Kodiak Sciences
KOD
 		$ 90.95 -7.67 % $ 4.84 B usaUSA
Karyopharm Therapeutics Karyopharm Therapeutics
KPTI
 		$ 0.06 -15.5 % $ 656 usaUSA
FSD Pharma FSD Pharma
HUGE
 		- 5743.5 % $ 69.7 M canadaCanada
BioAtla BioAtla
BCAB
 		$ 1.74 0.64 % $ 102 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
 		- - $ 3.85 B usaUSA
UroGen Pharma Ltd. UroGen Pharma Ltd.
URGN
 		$ 25.27 -12.07 % $ 1.22 B israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
 		$ 12.93 -6.44 % $ 1.16 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
 		- 1052.0 % $ 415 M usaUSA
Acasti Pharma Acasti Pharma
ACST
 		- 4.01 % $ 150 M canadaCanada
ADiTx Therapeutics ADiTx Therapeutics
ADTX
 		- - $ 374 usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
 		- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
 		- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
 		- - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
 		- 1.93 % $ 17.4 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
 		- 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
 		- 4.14 % $ 49.1 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
 		- - $ 5.18 B usaUSA
Athira Pharma Athira Pharma
ATHA
 		- - $ 269 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
 		- -52.27 % $ 4.45 M usaUSA
AVROBIO AVROBIO
AVRO
 		- 1083.1 % $ 745 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
 		- - $ 96.9 B britainBritain
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
 		- -2.5 % $ 5.88 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
 		- 0.49 % $ 251 B cayman-islandsCayman-islands
EyePoint Pharmaceuticals EyePoint Pharmaceuticals
EYPT
 		$ 0.36 -8.84 % $ 26.4 K usaUSA
Bio-Path Holdings Bio-Path Holdings
BPTH
 		- - $ 100 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
 		- -3.03 % $ 260 M usaUSA
ChromaDex Corporation ChromaDex Corporation
CDXC
 		- -0.88 % $ 598 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
 		- -16.75 % $ 25.8 M usaUSA